Recent Finacing
Recent Raise
C4 Therapeutics develops small-molecule targeted protein degraders that recruit the ubiquitin–proteasome system via Degronimid/TORPEDO platforms, combining chemistry, proprietary assays, high-throughput screening and predictive modeling to design clinical candidates.
